JP2009504157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504157A5 JP2009504157A5 JP2008526056A JP2008526056A JP2009504157A5 JP 2009504157 A5 JP2009504157 A5 JP 2009504157A5 JP 2008526056 A JP2008526056 A JP 2008526056A JP 2008526056 A JP2008526056 A JP 2008526056A JP 2009504157 A5 JP2009504157 A5 JP 2009504157A5
- Authority
- JP
- Japan
- Prior art keywords
- antiviral
- weeks
- albumin fusion
- fusion protein
- ribavirin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000009027 Albumins Human genes 0.000 claims 25
- 108010088751 Albumins Proteins 0.000 claims 25
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 20
- 108020001507 fusion proteins Proteins 0.000 claims 20
- 102000037865 fusion proteins Human genes 0.000 claims 20
- 239000003443 antiviral agent Substances 0.000 claims 18
- 230000000840 anti-viral effect Effects 0.000 claims 16
- 208000005176 Hepatitis C Diseases 0.000 claims 11
- 229960000329 ribavirin Drugs 0.000 claims 11
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 11
- 208000036142 Viral infection Diseases 0.000 claims 9
- 230000009385 viral infection Effects 0.000 claims 9
- 239000002532 enzyme inhibitor Substances 0.000 claims 7
- 229940125532 enzyme inhibitor Drugs 0.000 claims 7
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000002777 nucleoside Substances 0.000 claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 4
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 4
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- 229940122806 Cyclophilin inhibitor Drugs 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims 3
- 229960000517 boceprevir Drugs 0.000 claims 3
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical group O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims 3
- 239000000134 cyclophilin inhibitor Substances 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 230000002584 immunomodulator Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- XNDAUZRSIAEAAR-HNNXBMFYSA-N (4s)-5-amino-4-[3-[4-(5-methylthiophen-2-yl)phenyl]propanoylamino]-5-oxopentanoic acid Chemical compound S1C(C)=CC=C1C1=CC=C(CCC(=O)N[C@@H](CCC(O)=O)C(N)=O)C=C1 XNDAUZRSIAEAAR-HNNXBMFYSA-N 0.000 claims 1
- 101710153593 Albumin A Proteins 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70752105P | 2005-08-12 | 2005-08-12 | |
| US71238605P | 2005-08-31 | 2005-08-31 | |
| US73272405P | 2005-11-03 | 2005-11-03 | |
| US77691406P | 2006-02-28 | 2006-02-28 | |
| US78136106P | 2006-03-13 | 2006-03-13 | |
| US81018206P | 2006-06-02 | 2006-06-02 | |
| US81368206P | 2006-06-15 | 2006-06-15 | |
| PCT/US2006/029391 WO2007021494A2 (en) | 2005-08-12 | 2006-07-31 | Albumin fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504157A JP2009504157A (ja) | 2009-02-05 |
| JP2009504157A5 true JP2009504157A5 (https=) | 2010-02-04 |
Family
ID=37758042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008526056A Withdrawn JP2009504157A (ja) | 2005-08-12 | 2006-07-31 | アルブミン融合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1924596A4 (https=) |
| JP (1) | JP2009504157A (https=) |
| KR (1) | KR20080071119A (https=) |
| AU (1) | AU2006280312A1 (https=) |
| BR (1) | BRPI0614761A2 (https=) |
| CA (1) | CA2618476A1 (https=) |
| EC (1) | ECSP088262A (https=) |
| IL (1) | IL189246A0 (https=) |
| MA (1) | MA29836B1 (https=) |
| MX (1) | MX2008001865A (https=) |
| NO (1) | NO20081233L (https=) |
| TN (1) | TNSN08064A1 (https=) |
| WO (1) | WO2007021494A2 (https=) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| WO2007146038A2 (en) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2008033413A2 (en) * | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2450368A1 (en) | 2007-01-30 | 2012-05-09 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| US20110293557A1 (en) | 2008-06-13 | 2011-12-01 | Proyecto De Biomedicina Cima, S.L. | Conjugates for the administration of biologically active compounds |
| CN102378635A (zh) | 2009-01-16 | 2012-03-14 | 特瓦制药工业有限公司 | 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂 |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| KR20100100254A (ko) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물 |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| EP2493921B1 (en) * | 2009-10-30 | 2018-09-26 | Albumedix Ltd | Albumin variants |
| EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| EP2571992B1 (en) * | 2010-05-21 | 2018-04-25 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| WO2012118042A1 (ja) * | 2011-02-28 | 2012-09-07 | 独立行政法人国立循環器病研究センター | 悪性腫瘍転移抑制用医薬 |
| CA2830660A1 (en) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US9486507B2 (en) | 2011-06-10 | 2016-11-08 | Biogen Ma Inc. | Pro-coagulant compounds and methods of use thereof |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| DE202012012955U1 (de) | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| CN104271150A (zh) | 2012-01-12 | 2015-01-07 | 比奥根艾迪克Ma公司 | 嵌合因子viii多肽及其用途 |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| JP6256882B2 (ja) | 2012-02-15 | 2018-01-10 | アムニクス オペレーティング インコーポレイテッド | 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途 |
| DK2825556T3 (en) | 2012-03-16 | 2018-04-16 | Albumedix As | albumin Variants |
| CA2875247A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
| WO2013185113A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
| CN103525695B (zh) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | 便携式肾功能检测系统 |
| CN104661674A (zh) | 2012-07-11 | 2015-05-27 | 阿穆尼克斯运营公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| HK1213767A1 (zh) | 2012-10-18 | 2016-07-15 | Bioverativ Therapeutics Inc. | 使用固定劑量凝血因子的方法 |
| MX2015005363A (es) | 2012-11-08 | 2015-11-06 | Novozymes Biopharma Dk As | Variantes de albumina. |
| WO2014127215A1 (en) | 2013-02-15 | 2014-08-21 | Biogen Idec Ma Inc. | Optimized factor viii gene |
| US20160033523A1 (en) | 2013-02-16 | 2016-02-04 | Novozymes Biopharma Dk A/S | Pharmacokinetic animal model |
| WO2014144549A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Factor ix polypeptide formulations |
| CN113817069A (zh) | 2013-06-28 | 2021-12-21 | 比奥贝拉蒂治疗公司 | 具有xten的凝血酶可裂解连接子和其用途 |
| TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| HUE057005T2 (hu) | 2013-09-25 | 2022-04-28 | Bioverativ Therapeutics Inc | Oszlopon történõ vírusinaktiváló eljárások |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| AU2015204646B2 (en) | 2014-01-10 | 2020-08-27 | Bioverativ Therapeutics Inc. | Factor VIII chimeric proteins and uses thereof |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| BR112017007765B1 (pt) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
| JP7007261B2 (ja) | 2015-08-20 | 2022-01-24 | アルブミディクス リミティド | アルブミン変異体及びコンジュゲート |
| CN108367048B (zh) | 2015-10-02 | 2022-08-12 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| CA3012695A1 (en) | 2016-02-01 | 2017-08-10 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| EP3535585A1 (en) | 2016-11-04 | 2019-09-11 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| JP2019536794A (ja) | 2016-12-02 | 2019-12-19 | バイオベラティブ セラピューティクス インコーポレイテッド | 凝固因子に対する免疫寛容を誘導する方法 |
| US20200031895A1 (en) | 2016-12-16 | 2020-01-30 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| EA201991768A1 (ru) | 2017-01-31 | 2020-01-22 | Байоверетив Терапьютикс Инк. | Слитые белки на основе фактора ix и способы их получения и пути применения |
| JP2020517657A (ja) * | 2017-04-20 | 2020-06-18 | ノヴォ ノルディスク アー／エス | アルブミン融合タンパク質の精製方法 |
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| AU2019215063B2 (en) | 2018-02-01 | 2025-10-16 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
| PL3793588T3 (pl) | 2018-05-18 | 2025-09-01 | Bioverativ Therapeutics Inc. | Sposoby leczenia hemofilii a |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| JP7644007B2 (ja) | 2018-12-06 | 2025-03-11 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
| KR20220097891A (ko) | 2019-09-30 | 2022-07-08 | 바이오버라티브 테라퓨틱스 인크. | 렌티바이러스 벡터 제형 |
| MX2023000156A (es) | 2020-06-24 | 2023-02-16 | Bioverativ Therapeutics Inc | Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina. |
| JPWO2022030580A1 (https=) * | 2020-08-06 | 2022-02-10 | ||
| US12487299B2 (en) | 2022-06-20 | 2025-12-02 | Shanghai United Imaging Healthcare Co., Ltd. | Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices |
| WO2024080306A1 (ja) * | 2022-10-11 | 2024-04-18 | Ｊｃｒファーマ株式会社 | 血清アルブミンと生理活性を有する蛋白質との融合蛋白質 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005003296A2 (en) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| HUE027902T2 (en) * | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/en not_active Ceased
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/es not_active Application Discontinuation
- 2006-07-31 EP EP06813242A patent/EP1924596A4/en not_active Withdrawn
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/pt not_active IP Right Cessation
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/ko not_active Withdrawn
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/ja not_active Withdrawn
- 2006-07-31 CA CA002618476A patent/CA2618476A1/en not_active Abandoned
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/fr unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/no not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009504157A5 (https=) | ||
| JP2010503396A5 (https=) | ||
| Bhatia et al. | Sofosbuvir: A novel treatment option for chronic hepatitis C infection | |
| US20200276198A1 (en) | Combination therapy of an hbv capsid assembly inhibitor and an interferon | |
| US20110020272A1 (en) | Combination therapy for treating hepatitis viral infection | |
| JP2008255121A (ja) | 抗ｂ型肝炎ウイルス活性を有するヌクレオシド | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| KR20140010097A (ko) | B형 간염 바이러스 단독 감염 또는 델타 간염 바이러스와의 조합 감염 및 연관된 간 질환의 치료 | |
| Bergman et al. | Interferons as therapeutic agents for infectious diseases | |
| JP5209462B2 (ja) | コンセンサスインターフェロンの使用方法 | |
| Foster et al. | 57 ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: FINAL RESULTS OF STUDY C209 | |
| JP2016153402A (ja) | Ｃ型肝炎ウイルス感染症の新規治療 | |
| Jensen et al. | Future directions in therapy for chronic hepatitis C | |
| CN105381450A (zh) | 丙型肝炎病毒感染的新疗法 | |
| Sarrazin et al. | 964 INCIDENCE OF VIROLOGIC ESCAPE OBSERVED DURING ITMN-191 (R7227) MONOTHERAPY IS GENOTYPE DEPENDENT, ASSOCIATED WITH A SPECIFIC NS3 SUBSTITUTION, AND SUPPRESSED UPON COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN | |
| RU2009113604A (ru) | Слитые белки альбумина | |
| CN105749246A (zh) | 治疗丙肝病毒感染的阿拉泊韦 | |
| JP2002527397A5 (https=) | ||
| Krastev et al. | 58 RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B+ RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B+ RIBAVRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A) | |
| Ortiz et al. | New Drugs in Synthesis Research for Viral Diseases | |
| Ozeki | 963 SAFETY AND A ANTIVIRAL ACTIVITY OF A MONOTHERAPY WITH A MP-424 FOR 24 WEEKS IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1B INFECTION | |
| JP2014528947A (ja) | Ｃ型肝炎ウイルス感染症の治療のためのアリスポリビル | |
| Lampertico et al. | SAFETY AND TOLERABILITY OF EXTENDED (96 WEEKS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IN GENOTYPE D PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: 135 | |
| SAFETY et al. | EARLY VIRAL RESPONSE OF CONTROLLED-RELEASE INTERFERON ALPHA2B AND RIBAVIRIN VS. PEGYLATED-INTERFERON ALPHA2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 12 WEEK RESULTS (SELECT-2 TRIAL) |